Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (Weekly Intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Dunne, Michael W ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; IMMUNOGLOBULIN G; PLACEBO;

ADULT; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0034049838     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315634     Document Type: Conference Paper

References (24)

1. 1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340: 115-26.
2. 2. Ridker PM, Cushman M, Stampfer MJ, Tracey RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
3. 3. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6.
4. 4. Lacy F, O'Connor DT, Schmid-Schonlein GW. Plasma hydrogen peroxide production in hypertensives and normotensives at genetic risk for hypertension. J Hypertens 1998;16:291-303.
5. 5. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-5.
6. 6. Dunne MW. The association of Chlamydia pneumoniae and atherogenesis. In: Scheld WM, Craig WA, Hughes JM, eds. Emerging infections 2. Washington, DC: ASM Press, 1998:105-23.
7. 7. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997;35:48-52.
8. 8. Aldons MB, Grayston JT, Wang SP, Foy HM. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families. 1966-1979. J Infect Dis 1992;166:646-9.
9. 9. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992;15:757-63.
10. 10. Maass M, Gieffers J, Krause E, Engel PM, Bartels C, Solbach W. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med Microbiol Immunol 1998;187: 103-6.
11. 11. Boman J, Soderberg S, Forsberg J, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998;178:274-7.
12. 12. Fenelon LE. Mumtaz G, Ridgway GL. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 1990;26:763-7.
13. 13. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-4.
14. 14. Engel JN. Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. Antimicrob Agents Chemother 1992;36:2304-9.
15. 15. Hahn DL. Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial [see comments]. J Fam Prac 1995;41:345-51.
16. 16. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994;58: 686-99.
17. 17. Dunne MW, Foulds G, Retsema J. Rationale for the use of azithromycin as Mycobacterium avium chemoprophylaxis. Am J Med 1997;102:37-55.
18. 18. Oldfield EC, Fessel WJ, Dunne MW et al. Once weekly azithromycin therapy for the prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1998;26:611-9.
19. 19. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against dissemintaed Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
20. 20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
21. 21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
22. 22. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
23. 23. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
24. 24. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:649-53.